SOHO State of the Art Updates & Next Questions: Intensive and Non–Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

SOHO State of the Art Updates & Next Questions: Intensive and Non–Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Published:2021-08 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Short Nicholas J.^ORCID,Kantarjian Hagop,Jabbour Elias

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference38 articles.

1. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions;Samra;J Hematol Oncol,2020

2. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis;Berry;JAMA Oncol,2017

3. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia;Ravandi;Br J Haematol,2016

4. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia;Short;Blood,2016

5. Multicenter total therapy gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification;Chiaretti;Blood,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission;American Journal of Hematology;2024-02-05

2. Diagnosis and Molecular Pathology of Lymphoblastic Leukemias and Lymphomas in the Era of Genomics and Precision Medicine: Historical Evolution and Current Concepts—Part 2: B-/T-Cell Acute Lymphoblastic Leukemias;Lymphatics;2023-07-26

3. ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma;Onco;2022-10-14

4. Modern Management Options for Ph+ ALL;Cancers;2022-09-20

5. Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance;Cancer Drug Resistance;2022